Protect Yourself While There’s Still Time …

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

Junge Zhang Biography and Net Worth

Director of Ocugen

Dr. Junge (John) Zhang is the Founder, President, and CEO of Biopeptek, a company that specializes in the research and development of peptides. Since its founding in 2010, Dr. Zhang has established a company with over 50 experienced scientists and a state-of-the-art facility that is capable of producing high quality custom peptides for research and therapeutic uses. Through his many collaborations with major pharmaceutical companies and research institutions, Dr. Zhang is passionate about research to improve human health.

Prior to founding Biopeptek, Dr. Zhang was with the Janssen Pharmaceutical division of Johnson & Johnson. During his 9-year tenure at J&J, Dr. Zhang held numerous scientific and management positions and led multiple development projects related to three antibody drugs that received FDA approval. Prior to J&J, Dr. Zhang was a Senior Chemist at Eisai USA.

Dr. Zhang earned a Ph.D. in analytical chemistry from Drexel University, a M.S. in chemistry from University of Louisiana, and a B.S. in material science from Wuhan University of Technology in China. Dr. Zhang was born and raised in Qingdao China and immigrated to the United States to pursue his graduate education.

What is Junge Zhang's net worth?: The estimated net worth of Junge Zhang is at least $1.37 million as of June 14th, 2023. Mr. Zhang owns 1,077,182 shares of Ocugen stock worth more than $1,368,021 as of April 26th. This net worth approximation does not reflect any other investments that Mr. Zhang may own. Learn More about Junge Zhang's net worth.
How do I contact Junge Zhang?: The corporate mailing address for Mr. Zhang and other Ocugen executives is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. Ocugen can also be reached via phone at (484) 328-4701 and via email at [email protected]. Learn More on Junge Zhang's contact information.
Has Junge Zhang been buying or selling shares of Ocugen?: Junge Zhang has not been actively trading shares of Ocugen within the last three months. Most recently, on Wednesday, June 14th, Junge Zhang bought 200,278 shares of Ocugen stock. The stock was acquired at an average cost of $0.50 per share, with a total value of $100,139.00. Following the completion of the transaction, the director now directly owns 1,077,182 shares of the company's stock, valued at $538,591. Learn More on Junge Zhang's trading history.
Who are Ocugen's active insiders?: Ocugen's insider roster includes Kirsten Castillo (Director), Prabhavathi Fernandes (Director), Uday Kompella (Director), Ramesh Kumar (Director), Shankar Musunuri (CEO), Manish Potti (Director), Sanjay Subramanian (CFO), Vijay Tammara (SVP), and Junge Zhang (Director). Learn More on Ocugen's active insiders.
Are insiders buying or selling shares of Ocugen?: In the last twelve months, Ocugen insiders bought shares 1 times. They purchased a total of 200,278 shares worth more than $100,139.00. The most recent insider tranaction occured on June, 14th when Director Junge Zhang bought 200,278 shares worth more than $100,139.00. Insiders at Ocugen own 3.5% of the company. Learn More about insider trades at Ocugen.
Information on this page was last updated on 6/14/2023.

Junge Zhang Insider Trading History at Ocugen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/14/2023	Buy	200,278	$0.50	$100,139.00	1,077,182
11/3/2021	Sell	150,300	$17.32	$2,603,196.00
12/4/2019	Buy	220,000	$0.40	$88,000.00
11/27/2019	Buy	270,000	$0.37	$99,900.00	600,078
11/25/2019	Buy	115,000	$0.27	$31,050.00	215,078
11/22/2019	Buy	80,000	$0.28	$22,400.00	215,078
11/18/2019	Buy	100,000	$0.41	$41,000.00	135,078
10/11/2019	Buy	4,000	$1.82	$7,280.00
9/30/2019	Buy	31,078	$3.09	$96,031.02

Junge Zhang Buying and Selling Activity at Ocugen

Ocugen Company Overview

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Today's Range

Now: $1.27

$1.19

$1.31

50 Day Range

MA: $1.28

$0.79

$1.88

2 Week Range

Now: $1.27

$0.35

$2.11

Volume

4,641,086 shs

Average Volume

8,034,675 shs

Market Capitalization

$326.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.51